Low rate of intraperitoneal port placement in ovarian cancer patients, a population-based assessment. Issue 7 (September 2019)

• Record Type: Journal Article
• Authors: Buckingham, Lindsey; Koenig, Angela; Ko, Emily M; Brensinger, Colleen M; Latif, Nawar; Hummel, Charles; Zhang, Xiaochen; Morgan, Mark A; Burger, Robert A; Giuntoli II, Robert L
• Is Part Of: International journal of gynecological cancer. Volume 29:Issue 7(2019)
• Publication Date: 2019-09
• Subjects: ovarian cancer -- laparotomy -- operative time; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2019-000566
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction: The National Comprehensive Cancer Network (NCCN) guidelines recommend intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients. The objective of this investigation was to determine the rate of intraperitoneal port placement in patients undergoing surgery for ovarian cancer in a national database maintained by the American College of Surgeons. Method: We identified ovarian cancer patients in the National Surgical Quality Improvement Program database from 2006 to 2012. Demographics, comorbidities, operative outcomes, and postoperative complications were abstracted. Descriptive analyses were conducted using Wilcoxon rank-sum and Chi square tests, and multivariate regression models were used to analyze pre-operative and post-operative variables associated with intraperitoneal port placement. Results: We identified 2659 ovarian cancer patients who underwent primary surgical management. Of these patients, only 128 (4.8%) had an intraperitoneal port placed at the time of surgery. In multivariable analyses, intraperitoneal ports were associated with body mass index ⩽25, disseminated cancer, later portion of the study period (2009–2012), and operative time >200 min. Intraperitoneal port placement was not associated with any difference in surgical site infection, wound disruption, major postoperative complication, readmission within 30 days, or death within 30 days. Discussion: Recent investigation of practice at NCCN institutions between 2003 and 2012 found only 35% of eligible ovarian cancer patients received intraperitoneal chemotherapy. Using intraperitoneal port placement as a surrogate for intraperitoneal chemotherapy administration, our investigation suggests an even lower rate (4.8%) nationally.